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LungA B S T R A C T
Sarcoidosis is a granulomatous inflammatory disease that is induced by unknown antigen(s)
in a genetically susceptible host. Although the direct link betweenMycobacterium tuberculosis
(MTB) infection and sarcoidosis can be excluded on the basis of current knowledge, non-
infectiousmechanismsmay explain the causative role ofmycobacterial antigens. Ever since
sarcoidosiswas first described, its relationship with tuberculosis (TB) has been under-inves-
tigated.Whereas some researchers consider sarcoidosis andTB as twoexamples of the same
disease process, others have rejectedmycobacteria as playing any causative role in sarcoid-
osis.Whether they are linked causally or not, clinical evidencemakes a differential diagnosis
between the two conditions very challenging, particularly in countries with high burden of
TB. The present study analyzes the relationship between sarcoidosis and TB and its implica-
tions in clinical practice. The coincidence of TB and sarcoidosis and the higher incidence of
mycobacterial DNA in biological samples of sarcoid patients have been reported by many
authors. In addition, new evidence of a similarity in MTB phenotype in sarcoidosis is
provided. Overall, these observations suggest that TB and sarcoidosis may not only share
the same etiology, but may even be different aspects of one disease.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
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The incidence of non-tuberculous mycobacteria (NTM) infec-
tion has been increasingly reported both in immunocompro-
mised and immunocompetent patients. Pulmonary infections
due to NTM and Mycobacterium tuberculosis (MTB) are also
increasing worldwide [1]. Fast-growing NTM mycobacteria
are ubiquitous organisms in the environment and may cause
diseases in both healthy and immunocompromised patients.
As such, they are a recognized cause of environmentally
acquired diseases, including post-traumatic skin, soft tissue,
and bone infections, pulmonary disease [2–4], disseminated
infection [5] and cervical lymphadenitis [6]. Information
about the risk factors for NTM disease is unclear given that
the data comes from case reports and retrospective studies.
Many factors have been involved in the increased susceptibil-
ity of NTM, such as pre-existing lung disease, immune sup-
pression or genetic defects of cell-mediated immunity that
may be playing an important role [7]. Sarcoidosis is an idio-
pathic, multi-organ, inflammatory diseasewhich is character-
ized by the presence of epithelioid cell, non-caseating
granulomas in various organs [8–10]. The lungs, lymph nodes,
skin and eyes are the most commonly affected organs [11].
Yet the potential involvement of any organ system contrib-
utes to its myriad of clinical manifestations not well under-
stood. The etiology of sarcoidosis remains unknown; its
development is complex, with genetic susceptibility and
environmental factors that may be playing important roles
in the pathogenesis of diseases [12–14]. Furthermore, certain
occupations and environmental exposures have been linkedig. 1 – The cartoon indicating simple pathogenesis of Sarcoidos
ctivation of the T cells and APCs which leads to releasing of cyt
nd Th2 response which in turn induces the granuloma formati
esolution or chronic status of diseases with fibrosis condition. Mto the higher risk of sarcoidosis in some patients [15,16]. Since
the lungs are the most commonly affected organ, the search
for an etiologic agent has focused on airborne antigens and
infectious or non-infectious bacteria [17,18]. The use of
molecular tools and techniques demonstrating genomic or
protein material of mycobacterial origin in sarcoidosis tis-
sues, along with elevated humeral and cellular immune
response to Mycobacterial antigens, may support the hypoth-
esis that mycobacterial antigens may drive some cases of
sarcoidosis.
In addition, there is much clinical evidence supporting the
similarity between tuberculosis (TB) and sarcoidosis [19–24].
The present study provides a brief overview on the possible
role of mycobacterium in the pathogenesis of sarcoidosis
with a focus on the role of NTM. Finding a causal link between
the concomitant occurrence of TB and sarcoidosis will be a
challenge for the future, but will lead to the use of new ther-
apeutic drugs for suppressing lung inflammation in these
patients.Sarcoidosis
The immunopathology of sarcoidosis remains elusive despite
years of research into this multi-organ disease [25]. However,
recent studies have provided new insights into the genetics
and immune components involved in the clinical manifesta-
tion of the disease. Granulomatous inflammation is believed
to be the host immune response to a persistent poorly
degradable unknown antigen [25]. Although direct evidenceis Exposure of body to unknown sarcoid antigen leads to
okines. CD4 activation can skew the immune system to Th1
on. Formation of granuloma in later phases can end up to
ortaz et al., Iran J. Allergy Asthma Immunol. 2014;13(5):300–6
Fig. 2 – (A) Photomicrograph showing cell wall deficient
forms (CDWF) grown from the blood of a patient’s body as
seen in the center, and small yellow fluorescing with active
sarcoidosis using the Mycobacterium tuberculosis H37RV
monoclonal antibody. A large yellow fluorescing L
microcolonies (·400) are seen elsewhere. (Almenoff PL et al.,
Thorax 1996;51:530–3). (B) Atomic force microscopy shows
the cell wall deficient forms of M. tuberculosis during a
dormant phase of growth. (Farnia P et al. Int. J. Clin. Exp.
Med. 2010; 3:320–326).
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sarcoid granuloma reaction [26].
The immune mechanisms that cause this disease start
with the antigenic stimulus, followed by T-cell, macrophage
and dendritic cell activation via a classic MHC II–mediated
pathway (Fig. 1). The etiology of sarcoidosis is intriguing,
since a part of its definition (i.e., unknown cause) makes it
uniquely different from granulomatous disorders arising
from exposure to a known chronically persisting antigen,




Much remains to be understood in the pathogenesis of NTM
infections in humans as most of these organisms appear tolie at the edge of clinical pathogenicity. A combination of a
high-infecting dose, long-standing colonization of bacteria,
and host immune status decline may trigger an invasive dis-
ease whose clinical presentation may be misdiagnosed as a
recurrence of the underlying disease [28,29]. An increase in
the rate of NTM diseases in Western countries is associated
with a decline in the prevalence of TB [30].
Rather than an increase in prevalence, it is most likely due
to an increased number of immunocompromised patients fol-
lowing a longstanding disease and to the introduction of
more accurate methods for NTM identification. NTM diseases,
unlike MTB, are not reportable to public health authorities;
therefore, best estimates of their incidence are often based
on the progress in laboratory isolation of NTM. This has led
to the recognition of several new species associated with
human diseases, such as sarcoidosis [31]. It is believed that
granulomatous diseases of lungs may be the result of the con-
tinued presentation of an unknown poorly degradable anti-
gen [32,33]. With the increased ability to detect NTM
presence in sarcoidosis, this raises the possibility that MTB
and sarcoidosis may have a similar causal agent, namely
NTM, and that these may even be different clinical manifesta-
tions of the same disease in the patient.Does mycobacterium infection play a role in
sarcoidosis?
Mycobacteria are a class of bacteria which are very similar to
other bacteria, but possess some unique characteristics and
behaviors which induce many diverse diseases; for example,
M. tuberculosis causes TB, and mycobacterium leprae causes lep-
rosy [34]. Interestingly, both MTB and NTM have been isolated
from a majority of sarcoidosis patients [35–41]. Thus, it has
been suggested that sarcoidosis may be a clinical manifesta-
tion of this group of patients with infection by the mycobac-
teria who have a strong granulomatous response which
diminishes upon elimination of the mycobacteria [42].
To date, both infective (MTB) and non-infective (NTM)
mycobacteria have been implicated in sarcoidosis pathogene-
sis [43]. Despite this, the role of mycobacteria in sarcoidosis
remains unclear and needs to be elucidated in the future.
Non-infective agents have previously been implicated as
causal agents in sarcoidosis because of their epidemiological
association with disease [44], but this concept has not been
well understood [45]. Currently, the focus is on infective
agents, and the two strongest candidates are Propionibacte-
rium and mycobacterium [46]. Since sarcoidosis was first
described, there has always been a belief that the disease is
in some way related to MTB [47].
However, the inability to identify mycobacteria by histo-
logical staining or culture from pathological tissues continues
to be one of the strongest arguments against a potential role
for mycobacteria.
Some studies have suggested a promising association
between mycobacteria (both MTB and NTM) and sarcoidosis
[48]. In particular, slow-growing mycobacteria species with
low pathogenic potential, but with the capability of eliciting
a type IV immune response, may be important in sarcoidosis.
In support of this, Almenoff et al. in 1997 and Farnia et al.
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sarcoidosis patients with a similar phenotype to that seen in
TB, respectively (Fig. 2A and B), which provides further evi-
dence for a similar causal agent [49–51].
Whether or not mycobacterium in this form induces anti-
genicity to mimic sarcoidosis pathogenesis is better left to a
perspective study which needs to be elucidated in the future.
In order to confirm this hypothesis, it will be necessary to
perform large multi-center trials using a central laboratory for
mycobacteria sample testing.Conflict of interest
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